By directly targeting the cell cycle inhibitors, including CDKN1B/p27 and CDKN1C/p57, the influence of miR-221 on active progression of HCC is consistently disclosed in multiple studies [112]. Here, CDKN1B is linked to hepatocellular carcinoma.